https://www.selleckchem.com/pr....oducts/baricitinib-l
20, p=0.028), lymphovascular invasion (HR=127.5, p=0.003), and maximum standardized uptake value (HR=1.24, p=0.005) were poor prognostic predictors for RFS. Patients with IMA demonstrated RFS similar to and significantly better than that of patients with IASLC grades 2 and 3, respectively. For OS, IMA prognosis was between that of IASLC grades 2 and 3. Since the prognosis of IMA among lung adenocarcinomas appears to be relatively worse, further clinical studies investigating IMA-specific treatment and follow-up plans are n